Keros Therapeutics, Inc.

Keros Therapeutics, Inc.verified

KROS

Price:

$49.61

Market Cap:

$1.79B

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, whi...[Read more]

Industry

Biotechnology

IPO Date

2020-04-08

Stock Exchange

NASDAQ

Ticker

KROS

The PE Ratio as of July 2024 (TTM) for Keros Therapeutics, Inc. (KROS) is -9.63

According to Keros Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -9.63. This represents a change of 17.49% compared to the average of -8.20 of the last 4 quarters.

Keros Therapeutics, Inc. (KROS) Historical PE Ratio (quarterly & annually)

How has KROS PE Ratio performed in the past?

The mean historical PE Ratio of Keros Therapeutics, Inc. over the last ten years is -35.77. The current -9.63 PE Ratio has changed 2.59% with respect to the historical average. Over the past ten years (40 quarters), KROS's PE Ratio was at its highest in in the September 2023 quarter at -6.00. The PE Ratio was at its lowest in in the December 2021 quarter at -49.39.

Quarterly (TTM)
Annual

Average

-35.77

Median

-18.84

Minimum

-133.60

Maximum

-7.65

Keros Therapeutics, Inc. (KROS) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Keros Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 66.89%

Maximum Annual PE Ratio = -7.65

Minimum Annual Increase = -89.19%

Minimum Annual PE Ratio = -133.60

Quarterly (TTM)
Annual
YearPE RatioChange
2023-7.65-33.91%
2022-11.58-50.18%
2021-23.24-3.62%
2020-24.1166.89%
2019-14.45-89.19%

Keros Therapeutics, Inc. (KROS) Average PE Ratio

How has KROS PE Ratio performed in the past?

The current PE Ratio of Keros Therapeutics, Inc. (KROS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-14.16

5-year avg

-16.21

10-year avg

-35.77

Keros Therapeutics, Inc. (KROS) PE Ratio vs. Peers

How is KROS’s PE Ratio compared to its peers?

Keros Therapeutics, Inc.’s PE Ratio is greater than IDEAYA Biosciences, Inc. (-24.92), less than AnaptysBio, Inc. (-6.08), less than MeiraGTx Holdings plc (-3.98), less than Homology Medicines, Inc. (-0.01), greater than Janux Therapeutics, Inc. (-40.05), less than Fennec Pharmaceuticals Inc. (64.25), greater than Edgewise Therapeutics, Inc. (-17.59), less than Harmony Biosciences Holdings, Inc. (13.59), less than Aerovate Therapeutics, Inc. (-0.64), less than Syndax Pharmaceuticals, Inc. (-8.25), less than Mineralys Therapeutics, Inc. (-6.83), less than Replimune Group, Inc. (-2.95), less than Erasca, Inc. (-3.73), less than Century Therapeutics, Inc. (-1.12), less than NGM Biopharmaceuticals, Inc. (-0.91), less than Monte Rosa Therapeutics, Inc. (-1.97), less than Surrozen, Inc. (-0.47), less than Bolt Biotherapeutics, Inc. (-0.44), greater than Larimar Therapeutics, Inc. (-11.48), less than Kezar Life Sciences, Inc. (-0.48),

Build a custom stock screener for Keros Therapeutics, Inc. (KROS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Keros Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Keros Therapeutics, Inc. (KROS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Keros Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Keros Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Keros Therapeutics, Inc. (KROS)?

What is the highest PE Ratio for Keros Therapeutics, Inc. (KROS)?

What is the 3-year average PE Ratio for Keros Therapeutics, Inc. (KROS)?

What is the 5-year average PE Ratio for Keros Therapeutics, Inc. (KROS)?

How does the current PE Ratio for Keros Therapeutics, Inc. (KROS) compare to its historical average?